Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio Inc (NQ: PASG )

1.240 +0.010 (+0.81%)
Streaming Delayed Price Updated: 1:46 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Passage Bio Inc

< Previous 1 2 3 Next >
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Recap: Passage Bio Q3 Earnings
Via Benzinga
Recap: Passage Bio Q1 Earnings
Via Benzinga
Passage Bio's Earnings: A Preview
Via Benzinga
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Although nano-cap stocks are super-risky just like stealing bases in baseball, there may be a time and place for extreme speculation. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results. 
Via Benzinga
Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities
Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated... 
Via Benzinga
Expert Ratings for Passage Bio
Via Benzinga
Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Passage Bio And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 33 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
  
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Passage Bio Commences Initial-Stage Brain Disorder Study
Passage Bio (NASDAQ: PASG) has dosed the first patient in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.